A. Beelen

Biodistribution of 18F-FES in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant (G1T48), a Novel Selective ER Degrader

R. Boellaard, R. Schuit, A. Windhorst, 2021, The Journal of Nuclear Medicine.

Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.

H. Rugo, S. Goel, A. Tan, 2022, Future oncology.

Population pharmacokinetics and exposure–response of trilaciclib in extensive‐stage small cell lung cancer and triple‐negative breast cancer

J. Marier, B. Rich, J. Bullock, 2022, British journal of clinical pharmacology.

Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)

P. Neven, E. Dees, J. E. Boers, 2019, Annals of Oncology.

TREATMENT OF EGFR-DRIVEN CANCER WITH FEWER SIDE EFFECTS

J. Bisi, J. Strum, J. Sorrentino, 2018 .

201P Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Preliminary phase II results

A. Bardia, D. Patt, M. Danso, 2023, ESMO Open.